Shares of VISEN PHARMA-B (02561) experienced a notable intraday surge, climbing more than 7% at one point. As of the latest update, the stock was up 4.7%, trading at HK$20.96.

The catalyst for this movement stems from a significant development. Under the policy support of the Beijing Rare Disease Drug Guarantee Pilot Zone, Peking University Third Hospital has formally introduced palopegteriparatide. This therapy is recognized as the world's first and only approved parathyroid hormone (PTH) replacement treatment for adult patients with chronic hypoparathyroidism.

This successful implementation signifies an expansion of the coverage for rare disease drug access within China's pilot zones. It also marks an acceleration in the availability of globally innovative medicines in the country. The treatment paradigm for hypoparathyroidism is now progressing from traditional symptom management towards a new era of physiological hormone replacement.

The introduced drug, palopegteriparatide, is a PTH prodrug developed using the TransCon technology platform. It boasts an extended half-life of approximately 60 hours. As the first and only hormone replacement therapy approved globally for adult chronic hypoparathyroidism, it works through a once-daily subcutaneous injection. This method enables the sustained release of active parathyroid hormone, aiming to achieve a hormone replacement effect that closely mimics the body's natural physiological state.

It is understood that palopegteriparatide is one of the core pipeline products for VISEN PHARMA. The company holds exclusive rights for its development, production, and commercialization across Greater China, encompassing mainland China, Hong Kong, Macau, and Taiwan.